Form 4: Monopar Therapeutics CFO Granted Stock Options
SEC Form 4 Filing
Karthik Radhakrishnan, CFO of Monopar Therapeutics, was granted 125,000 stock options on July 1, 2024, according to a Form 4 filing.
Summary
- Karthik Radhakrishnan, the Chief Financial Officer of Monopar Therapeutics, received 125,000 stock options on July 1, 2024.
- The options have an exercise price of $0.7414.
- The options vest in installments, starting with 15,625 shares vesting on December 31, 2024.
- The remaining options vest monthly at a rate of 1/48th of the total until fully vested on July 1, 2028.
- The options expire on June 30, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine grant of stock options, which is generally viewed as a positive incentive for management but doesn't necessarily indicate a significant shift in the company's prospects.
Positives
- The granting of stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term performance and commitment from the CFO.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. The vesting schedule is typical for such grants.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
- Companies like Amgen, Gilead Sciences, and Biogen typically use stock options with similar vesting schedules (e.g., four-year vesting) to incentivize their executives.
- The exercise price of $0.7414 would be compared to the current market price of MNPR stock to assess the potential value to the CFO.
- The size of the grant (125,000 options) would be benchmarked against grants to CFOs at comparable companies based on market capitalization and stage of development.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CFO to improve company performance.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of stock option grant: 125,000 options granted to Karthik Radhakrishnan. |
| 12/31/2024 | First vesting date: 15,625 shares vest. |
| 07/01/2028 | Final vesting date: Stock options are fully vested. |
| 06/30/2034 | Expiration date of the stock options. |
| 07/03/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.